Antimicrobial Resistance đŠ
https://antimicrobialresistance.substack.com/
AMR-related Inspirational Works
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
Antimicrobial Resistance Collaborators
Lancet, 399, 629â655 (2022)
Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections
BALANCE Investigators, Canadian Critical Care Trials Group, Association of Medical Microbiology and Infectious Disease Canada Clinical Research Network, Australian and New Zealand Intensive Care Society Clinical Trials Group, Australasian Society for Infectious Diseases Clinical Research Network, Daneman N, Rishu A, Pinto R, Rogers BA, Shehabi Y, Parke R, Cook D, Arabi Y, Muscedere J, Reynolds S, Hall R, Dwivedi DB, McArthur C, McGuinness S, Yahav D, Coburn B, Geagea A, Das P, Shin P, Detsky M, Morris A, Fralick M, Powis JE, Kandel C, Sligl W, Bagshaw SM, Singhal N, Belley-Cote E, Whitlock R, Khwaja K, Morpeth S, Kazemi A, Williams A, MacFadden DR, McIntyre L, Tsang J, Lamontagne F, Carignan A, Marshall J, Friedrich JO, Cirone R, Downing M, Graham C, Davis J, Duan E, Neary J, Evans G, Alraddadi B, Al Johani S, Martin C, Elsayed S, Ball I, Lauzier F, Turgeon A, Stelfox HT, Conly J, McDonald EG, Lee TC, Sullivan R, Grant J, Kagan I, Young P, Lawrence C, O'Callaghan K, Eustace M, Choong K, Aslanian P, Buehner U, Havey T, Binnie A, Prazak J, Reeve B, Litton E, Lother S, Kumar A, Zarychanski R, Hoffman T, Paterson D, Daley P, Commons RJ, Charbonney E, Naud JF, Roberts S, Tiruvoipati R, Gupta S, Wood G, Shum O, Miyakis S, Dodek P, Kwok C, Fowler RA
N Engl J Med, 392, 1065â1078 (2025)
Definitions and guidelines for research on antibiotic persistence
Balaban, Helaine, Lewis, et al.
Nat Rev Microbiol, 17, 441â448 (2019)
Testing physiologically relevant conditions in minimal inhibitory concentration assays
Belanger, Hancock
Nat Protoc, 16, 3761â3774 (2021)
Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America
Boucher, Talbot, Bradley, et al.
Clin Infect Dis, 48, 1â12 (2009)
The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome
Bryant JA, VuliÄ M, Walsh EA, Allen EG Jr, Beauchemin NJ, Chafee ME, Diao L, Fenn K, Ford KA, Hasson BR, Litcofsky KD, Lombardo MJ, Martinez A, O'Brien EJ, Straub TJ, Sykes SM, Marshall LF, Winkler JA, McGovern BH, Ford CB, Wortman JR, Henn MR
Nat Med, 32, 186â196 (2026)
Cloxacillin versus cefazolin for meticillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): a prospective, open-label, multicentre, non-inferiority, randomised clinical trial
Burdet C, SaĂŻdani N, Dupieux C, Lemaignen A, CanouĂŻ E, Surgers L, Vareil MO, Lefort A, Lepeule R, Peiffer-Smadja N, Charmillon A, Le Moing V, Boutoille D, Tolsma V, Abgrall S, Wolff M, Tattevin P, Esposito-FarĂšse M, Vandenesch F, Duval X, Tubiana S, Lescure FX, CloCeBa Study Group
Lancet, 406, 2349â2359 (2025)
Molecular mechanisms of antibiotic resistance revisited
Darby, Trampari, Siasat, et al.
Nat Rev Microbiol, 21, 280â295 (2023)
Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050
GBD 2021 Antimicrobial Resistance Collaborators
Lancet, 404, 1199â1226 (2024)
Efficacy, Safety, Pharmacokinetics, and Microbiome Changes of Ibezapolstat in Adults with Clostridioides difficile Infection: A Phase 2a Multicenter Clinical Trial
Garey KW, McPherson J, Dinh AQ, Hu C, Jo J, Wang W, Lancaster CK, Gonzales-Luna AJ, Loveall C, Begum K, Jahangir Alam M, Silverman MH, Hanson BM
Clin Infect Dis, 75, 1164â1170 (2022)
Cloxacillin plus fosfomycin versus cloxacillin alone for methicillin-susceptible Staphylococcus aureus bacteremia: a randomized trial
Grillo S, Pujol M, MirĂł JM, LĂłpez-Contreras J, Euba G, Gasch O, Boix-Palop L, Garcia-PaĂs MJ, PĂ©rez-RodrĂguez MT, Gomez-Zorrilla S, Oriol I, LĂłpez-CortĂ©s LE, Pedro-Botet ML, San-Juan R, Aguado JM, Gioia F, Iftimie S, Morata L, Jover-SĂĄenz A, GarcĂa-Pardo G, Loeches B, Izquierdo-CĂĄrdenas Ă, Goikoetxea AJ, Gomila-Grange A, Dietl B, Berbel D, Videla S, Hereu P, PadullĂ©s A, PallarĂšs N, TebĂ© C, Cuervo G, CarratalĂ J, SAFO study group
Nat Med, 29, 2518â2525 (2023)
Microtiter plate assays to assess antibiofilm activity against bacteria
Haney, Trimble, Hancock
Nat Protoc, 16, 2615â2632 (2021)
Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia
Holland TL, Cosgrove SE, Doernberg SB, Jenkins TC, Turner NA, Boucher HW, Pavlov O, Titov I, Kosulnykov S, Atanasov B, Poromanski I, Makhviladze M, Anderzhanova A, Stryjewski ME, Assadi Gehr M, Engelhardt M, Hamed K, Ionescu D, Jones M, Saulay M, Smart J, Seifert H, Fowler VG Jr, ERADICATE Study Group
N Engl J Med, 389, 1390â1401 (2023)
Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial
Kaasch AJ, LĂłpez-CortĂ©s LE, RodrĂguez-Baño J, Cisneros JM, Dolores Navarro M, FĂ€tkenheuer G, Jung N, Rieg S, Lepeule R, Coutte L, Bernard L, Lemaignen A, Kösters K, MacKenzie CR, Soriano A, Hagel S, Fantin B, Lafaurie M, Talarmin JP, Dinh A, Guimard T, Boutoille D, Welte T, Reuter S, Kluytmans J, Martin ML, Forestier E, Stocker H, Vitrat V, Tattevin P, Rommerskirchen A, Noret M, Adams A, Kern WV, Hellmich M, Seifert H, SABATO study group
Lancet Infect Dis, 24, 523â534 (2024)
Antibiotic susceptibility testing using minimum inhibitory concentration (MIC) assays
KadeĆĂĄbkovĂĄ, Mahmood, Mavridou
NPJ Antimicrob Resist, 2, 37 (2024)
A new antibiotic kills pathogens without detectable resistance
Ling L, Schneider T, Peoples A
Nature, 517, 455â459 (2015)
Fidaxomicin versus vancomycin for Clostridium difficile infection
Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK, OPT-80-003 Clinical Study Group
N Engl J Med, 364, 422â431 (2011)
Cryo-EM structure of a type IV secretion system
Macé, Vadakkepat, Redzej, et al.
Nature, 607, 191â196 (2022)
Multi-omic profiling a defined bacterial consortium for treatment of recurrent Clostridioides difficile infection
Menon R, Bhattarai SK, Crossette E, Prince AL, Olle B, Silber JL, Bucci V, Faith J, Norman JM
Nat Med, 31, 223â234 (2025)
A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response
Okhuysen PC, Ramesh MS, Louie T, Kiknadze N, Torre-Cisneros J, de Oliveira CM, Van Steenkiste C, Stychneuskaya A, Garey KW, Garcia-Diaz J, Li J, Duperchy E, Chang BY, Sukbuntherng J, Montoya JG, Styles L, Clow F, James D, Dubberke ER, Wilcox M
Clin Infect Dis, 78, 1462â1472 (2024)
Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study
Pirnay JP, Djebara S, Steurs G
Nat Microbiol, 9, 1434â1453 (2024)
Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances
Wiegand, Hilpert, Hancock
Nat Protoc, 3, 163â75 (2008)
Discovery of a structural class of antibiotics with explainable deep learning
Wong, Zheng, Valeri, et al.
Nature, 626, 177â185 (2024)
High-resolution landscape of an antibiotic binding site
Yang, Cameranesi, Gowder, et al.
Nature, 622, 180â187 (2023)
A novel antibiotic class targeting the lipopolysaccharide transporter
Zampaloni C, Mattei P, Bleicher K, Winther L, ThĂ€te C, Bucher C, Adam JM, Alanine A, Amrein KE, Baidin V, Bieniossek C, Bissantz C, Boess F, Cantrill C, Clairfeuille T, Dey F, Di Giorgio P, du Castel P, Dylus D, Dzygiel P, Felici A, GarcĂa-Alcalde F, Haldimann A, Leipner M, Leyn S, Louvel S, Misson P, Osterman A, Pahil K, Rigo S, SchĂ€ublin A, Scharf S, Schmitz P, Stoll T, Trauner A, Zoffmann S, Kahne D, Young JAT, Lobritz MA, Bradley KA
Nature, 625, 566â571 (2024)
Early Oral Antibiotic Switch in Staphylococcus aureus Bacteraemia: The Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Early Oral Switch Protocol
de Kretser D, Mora J, Bloomfield M, Campbell A, Cheng MP, Guy S, Hensgens M, Kalimuddin S, Lee TC, Legg A, Mahar RK, Marks M, Marsh J, McGlothin A, Morpeth SC, Sud A, Ten Oever J, Yahav D, Bonten M, Bowen AC, Daneman N, van Hal SJ, Heriot GS, Lewis RJ, Lye DC, McQuilten Z, Paterson DL, Owen Robinson J, Roberts JA, Scarborough M, Webb SA, Whiteway L, Tong SYC, Davis JS, Walls G, Goodman AL, SNAP Early Oral Switch Domain-Specific Working Group and SNAP Global Trial Steering Committee, SNAP Trial Group
Clin Infect Dis, 79, 871â887 (2024)
No matching items
AMR-related Lab Publications
No matching items
AMR-related Publications by Mechanism
Target Modification
No matching items
Agent Inactivation
No matching items
Agent Influx/Efflux
No matching items
Target Bypass
No matching items